Table 3

Univariate analyses of factors potentially associated with response to brentuximab vedotin

FactorObjective response*
PFS
Odds ratio95% CIPHazard ratio95% CIP
Total no. of prior regimens 1.07 0.87-1.32 .54 0.96 0.82-1.13 .65 
Prior autoSCT, yes/no 0.90 0.14-5.65 .91 2.75 0.57-13.23 .21 
Prior DLI, yes/no 2.75 0.40-18.87 .30 0.53 0.11-2.50 .42 
Prior external beam radiation, yes/no 2.00 0.16-25.40 .59 0.98 0.21-4.66 .98 
No. of prior systemic chemotherapy regimens 1.01 0.76-1.33 .96 0.97 0.78-1.19 .74 
AlloSCT       
    Donor source       
        Matched, related 4.67 0.40-53.95 .42 0.62 0.12-3.31 .58 
        Matched, unrelated 5.33 0.38-75.77 .36 0.77 0.13-4.52 .77 
        Other Ref. Ref.  Ref. Ref.  
    Time to disease progression, < 6 mo vs ≥ 6 mo 0.60 0.10-3.50 .57 2.68 0.56-12.87 .22 
No. of regimens in the interval between alloSCT and brentuximab vedotin 1.05 0.85-1.28 .67 0.98 0.83-1.15 .77 
Most recent regimen 
    Objective response, yes/no 0.61 0.13-2.98 .54 0.50 0.13-1.97 .32 
    Time to disease progression, < 6 mo vs ≥ 6 mo 1.13 0.20-6.05 .89 1.20 0.29-4.95 .80 
Any prior GVHD, yes/no 0.89 0.17-4.78 .89 1.28 0.36-4.52 .70 
FactorObjective response*
PFS
Odds ratio95% CIPHazard ratio95% CIP
Total no. of prior regimens 1.07 0.87-1.32 .54 0.96 0.82-1.13 .65 
Prior autoSCT, yes/no 0.90 0.14-5.65 .91 2.75 0.57-13.23 .21 
Prior DLI, yes/no 2.75 0.40-18.87 .30 0.53 0.11-2.50 .42 
Prior external beam radiation, yes/no 2.00 0.16-25.40 .59 0.98 0.21-4.66 .98 
No. of prior systemic chemotherapy regimens 1.01 0.76-1.33 .96 0.97 0.78-1.19 .74 
AlloSCT       
    Donor source       
        Matched, related 4.67 0.40-53.95 .42 0.62 0.12-3.31 .58 
        Matched, unrelated 5.33 0.38-75.77 .36 0.77 0.13-4.52 .77 
        Other Ref. Ref.  Ref. Ref.  
    Time to disease progression, < 6 mo vs ≥ 6 mo 0.60 0.10-3.50 .57 2.68 0.56-12.87 .22 
No. of regimens in the interval between alloSCT and brentuximab vedotin 1.05 0.85-1.28 .67 0.98 0.83-1.15 .77 
Most recent regimen 
    Objective response, yes/no 0.61 0.13-2.98 .54 0.50 0.13-1.97 .32 
    Time to disease progression, < 6 mo vs ≥ 6 mo 1.13 0.20-6.05 .89 1.20 0.29-4.95 .80 
Any prior GVHD, yes/no 0.89 0.17-4.78 .89 1.28 0.36-4.52 .70 

95% CI indicates 95% confidence interval.

*

Objective response was evaluated using logistical regression and PFS was evaluated using Cox regression. Two-sided P values are presented.

Includes autoSCT, alloSCT, DLI, systemic chemotherapy, and external beam radiation. Conditioning therapy for SCT is not counted as a separate regimen.

Most recent regimen prior to initiation of brentuximab vedotin therapy.

Close Modal

or Create an Account

Close Modal
Close Modal